1323407-86-8

Basic information

• Product Name: 3-[4-[[4-(bromomethyl)phenyl]methoxy]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione
• Synonyms: 3-[4-[[4-(bromomethyl)phenyl]methoxy]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione
• CAS NO: 1323407-86-8
• Molecular Weight: 443.297
• Mol File: 1323407-86-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3-[4-[[4-(bromomethyl)phenyl]methoxy]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[4-[[4-(bromomethyl)phenyl]methoxy]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione(1323407-86-8)
• EPA Substance Registry System: 3-[4-[[4-(bromomethyl)phenyl]methoxy]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione(1323407-86-8)

Safety Data

• Hazardous Substances Data: 1323407-86-8(Hazardous Substances Data)

Upstream product

• 603-80-5 3-hydroxy 2-methylbenzoic acid 
• 55289-05-9 methyl 3-hydroxy-2-methylbenzoate 
• 359629-73-5 3-(tert-butyl-dimethyl-silanyloxy)-2-methyl-benzoic acid methyl ester 
• 1323404-89-2 3-[4-[[4-(hydroxymethyl)phenyl]methoxy]-1-oxoisoindolin-2-yl]piperidine-2,6-dione 
• 125320-20-9 4-(bromomethyl)-t-butyldimethylsilyloxymethylbenzene 
• 118992-89-5 [4-({[tert-butyl(dimethyl)silyl]oxy}methyl)phenyl]methanol 
• 589-29-7 p-xylylene glycol 
• 623-24-5 1,4-bis(bromomethyl)benzene 
• 112159-16-7 2-((tert-butoxycarbonyl)amino)-5-methoxy-5-oxopentanoic acid 
• 617-65-2 Glutamic acid 
• 1499-55-4 DL-glutamic acid-5-methyl ester 
• 1323290-64-7 methyl 4,5-diamino-5-oxo-pentanoate hydrochloride 
• 1323407-17-5 2-bromomethyl-3-(tert-butyl-dimethyl-silanyloxy)-benzoic acid methyl ester 
• 1323407-16-4 4-carbamoyl-4-(4-hydroxy-1-oxo-1,3-dihydro-isoindol-2-yl)-butyric acid methyl ester 

Downstream Products

• 1323403-45-7 3-{1-Oxo-4-[4-(4-phenyl-imidazol-1-ylmethyl)-benzyloxy]-1,3-dihydro-isoindol-2-yl}-piperidine-2,6-dione 
• 1323406-05-8 3-(4-[4-[4-(3-FLUORO-PHENYL)-PIPERIDIN-1-YLMETHYL]-BENZYLOXY]-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE 
• 1323403-62-8 3-{4-[4-(2-Methyl-4-phenyl-imidazol-1-ylmethyl)-benzyloxy]-1-oxo-1,3-dihydro-isoindol-2-yl}-piperidine-2,6-dione 
• 1323403-89-9 3-{4-[4-(3,3-difluoro-azetidin-1-ylmethyl)-benzyloxy]-1-oxo-1,3-dihydro-isoindol-2-yl}-piperidine-2,6-dione 
• 1323403-87-7 3-(4-{4-[3-(4-fluoro-phenoxy)-azetidin-1-ylmethyl]-benzyloxy}-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione formate 
• 1323405-82-8 3-(4-((4-((4-(METHYLSULFONYL)PIPERIDIN-1-YL)METHYL) BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE 
• 1323403-93-5 3-{-4-[4-(3,3-difluoro-pyrrolidin-1-ylmethyl)-benzyloxy]-1-oxo-1,3-dihydro-isoindol-2-yl}-piperidine-2,6-dione 
• 1323403-11-7 3-(4-((4-((2-METHYL-1H-IMIDAZOL-1-YL)METHYL)BENZYL) OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE 
• 1323405-88-4 3-[4-[4-(4-ETHANESULFONYL-PIPERAZIN-1-YLMETHYL)-BENZYLOXY]-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL]-PIPERIDINE-2,6-DIONE 
• 1323404-00-7 3-{1-Oxo-4-[4-(3-phenyl-5,6-dihydro-8H-imidazo[1,2-a]pyrazin-7-ylmethyl)-benzyloxy]-1,3-dihydro-isoindol-2-yl}-piperidine-2,6-dione 
• 1323403-02-6 3-{1-oxo-4-[4-(1-oxo-thiomorpholin-4-ylmethyl)-benzyloxy]-1,3-dihydro-isoindol-2-yl}-piperidine-2,6-dione 
• 1323405-90-8 3-(1-oxo-4-{4-[4-(propane-2-sulfonyl)-piperazin-1-ylmethyl]-benzyloxy}-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione 

Relevant articles and documents

CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE

Bivalent compounds composition comprises one or more of the bivalent compounds. The bivalent compound comprises a cyclic-AMP response element binding protein (CBP) and/or adenoviral E1A binding protein of 300kDa (P300) ligand (CBP/P300 ligand) conjugated

METHODS FOR TREATING MULTIPLE MYELOMA AND THE USE OF COMPANION BIOMARKERS FOR 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE

A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.

ANTIPROLIFERATIVE COMPOUNDS AND BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 FOR COMBINED USE

Provided herein is are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l- oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof and a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3e (CD3) provided herein, in treating, preventing or managing multiple myeloma.